This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In an ongoing effort to reduce the backlog of patentapplications, Brazil has introduced new appellate stage guidelines that significantly impact how applicants should respond to office actions and file appeals.
Court of Appeals for the Federal Circuit (CAFC) in a precedential decision today vacated a Patent Trial and Appeal Board (PTAB) finding that certain claims of Google, LLC’s U.S. PatentApplication No. 14/628,093 were obvious. The CAFC opinion, authored by Chief Judge Moore, said the U.S.
Patent and Trademark Office (USPTO) announced a Deferred Subject Matter Eligibility Response Pilot Program (the “DSMER Program”). Currently, the USPTO applies a “compact prosecution approach” in examining patentapplications. An applicant is required to address all these objections and rejections in one response. .
Patent and Trademark Office (USPTO), discussing the issue of inconsistent statements made by patentapplicants pursuant to their disclosure requirements at the USPTO and other federal agencies, especially the U.S. Food and Drug Administration (FDA).
These Guidelines instruct European patent examiners (and the public) on how the patentprosecution process works—much like the United States Patent and Trademark Office’s (USPTO’s) Manual of Patent Examining Procedure.
Patents that are expected to protect a company’s most valuable innovations must stake a claim to that innovation and be equipped to defend it. This is because being worthy of patent protection doesn’t guarantee that an application’s claims to an innovation will not be rejected and rights to that innovation jeopardized.
Patent and Trademark Office (USPTO) announced a Deferred Subject Matter Eligibility Response Pilot Program (the “DSMER Program”). Currently, the USPTO applies a “compact prosecution approach” in examining patentapplications. An applicant is required to address all these objections and rejections in one response. .
Patent and Trademark Office (USPTO) in recent weeks regarding the Office’s decision to retire Private PAIR and EFS-Web, the two main software systems used by patentapplicants, on November 8. Numerous letters have been submitted to the U.S.
Inventorship in the US is a critical component of patent ownership. When applying for a patent at the USPTO, the applicant must name all inventors of the invention claimed in the patentapplication. In Europe, Article 123(2) EPC sets very strict requirements for amendments to patentapplications.
Having freelanced as a patent research analyst, he developed an interest in patentprosecution and in exploring the Patents Act through various interpretative approaches. He is currently engaged in WIPO-Harvard Law School Course in Patent Law and Global Public Health. course at NLSIU Bangalore. Article 3.2
Since the summer of 2020, the Canadian federal government has been looking for ways to decrease the needless delays and unwanted wait times present in the patent process under the Patent Rules. Shawn Dhue is an IPilogue Writer and a 2L JD Candidate at Osgoode Hall Law School. .
With South Africa’s patent office having recently granted the first patent to an AI inventor, and an Australian court ruling in favor of AI inventorship, it’s time to review how we got here—and where we’re going. If AI-related patentapplications and grants are on the uptick, what was the problem with DABUS?
companies and inventors still filed more patentapplications with the European Patent Office (EPO) than any other country, according to its Patent Index 2022, which was released today. patentapplications numbered 48,088, a 2.9% The index showed that U.S. increase from 2021.
Court of Appeals for the Federal Circuit (CAFC) today affirmed a Patent Trial and Appeal Board (PTAB) decision that upheld an examiners rejection of certain claims of a patentapplication for a cancer immunotherapy invention. The opinion was authored by Judge Lourie.
Patent and Trademark Office (USPTO) today announced the findings of two reports conducted by third-party academic economists and submitted to Congress late last year, as required by the Unleashing American Innovators Act of 2022 (UAIA).
The rules, if passed, are surely a strong attempt towards fighting the long-standing issue of pendency in the Indian Patent Office, but concurrently it can also led to dilution of material safeguards within the Patent Act, which are in place to ensure that applicants/ patentees stick to their end of the patent bargain.
That is to say, ‘applicants’ are interested stakeholders here, and focusing on issues faced by applicants alone, just one of the many stakeholders, does not equate to understanding the patent oppositions mechanism as a whole. of the total published applications. ’. of patentapplications)?
Patent and Trademark Office (USPTO) on Wednesday, October 3, issued a final order terminating approximately 3,100 patentapplications for intent to deceive the Office via fraudulent “S-signatures.”
Patent and Trademark Office (USPTO) office actions on the merits, a patentapplicant has the option to appeal the patent examiner’s decision rejecting one or more claims to a higher forum, i.e., the Patent Trial and Appeal Board (PTAB). After two or more U.S.
government since 1863 (the “Lincoln Law”) and is designed as a mechanism for catching (and thus deterring) fraud against the Federal Government. government and will then receive a portion of any recovered damages (15-30% depending upon whether the Gov’t steps in to do the litigating). 3730(e)(4)(A) (2010).
Patent and Trademark Office (USPTO) published a notice of proposed rulemaking (NPRM) in the Federal Register announcing that the agency would be revising its rules of practice to require that information disclosure statements related to patent term adjustments (PTAs) be submitted on Form PTO/SB/133.
Patent and Trademark Office’s (USPTO) Office of the Chief Economist (OCE) published a report detailing patentapplication filing trends at the USPTO related to COVID-19 diagnostics technologies. On October 23, the U.S.
A typical utility nonprovisional patentapplication will receive at least one Office Action rejecting the claims. Amendments are, therefore, common and to be expected in the normal course of patentprosecution. Think of the patent process as a negotiation with the US government.
In both cases, the Government argued that the Court’s recent decisions have strayed from earlier precedent and have fostered uncertainty regarding the patent eligibility standards. Additionally, if you are a patent owner or inventor, please include the number of U.S. Patentprosecution strategy and portfolio management; b.
Delhi High Court on Non-filing of Written Submission to Delay PatentApplication Process. The Controller of Patents where it rebuked the Plaintiff for not filing written submissions in time and thereby delaying the patentapplication process. Course on Access to Medicines, TRIPS and Patents [Kochi, December 10-14].
In view of this notice, life sciences companies should consider involving patent counsel in the review of relevant FDA submissions for possible inconsistencies with PTO filings and determination of the appropriate course of action where material inconsistencies are found to exist. What This Means for Life Sciences PatentApplicants.
In a recent post , we discussed whether patentapplications could provide insight into the blueprints of extraterrestrial spacecraft. Yet, an enigmatic question looms large: would the powers that be genuinely consider patenting such advanced technology, fully aware that patentapplications might see the light of day?
In a recent post , we discussed whether patentapplications could provide insight into the blueprints of extraterrestrial spacecraft. Yet, an enigmatic question looms large: would the powers that be genuinely consider patenting such advanced technology, fully aware that patentapplications might see the light of day?
In a recent post , we discussed whether patentapplications could provide insight into the blueprints of extraterrestrial spacecraft. Yet, an enigmatic question looms large: would the powers that be genuinely consider patenting such advanced technology, fully aware that patentapplications might see the light of day?
The ratio set by them are so diverse that, in an adversarial proceeding such as patentprosecution or litigation, the opposite parties may pick their respective chosen or desired positions based on any of them, and no clear conclusion could be arrived at.
Suggestions for intra-agency collaboration included more access to drug dossier information during patentprosecution, although concerns were also raised regarding the prospect that such increased engagement could tax agency resources to the detriment of all patentapplicants.
The case thus raises questions about the extent to which legal pleadings and motions, as petitions to the government for redress, are protected speech. Similar issues also came up in the patent information disclosure statement cases a decade ago. In American Institute of Physics v. 2013 WL 6242843, at *1 (N.D.
In this decision, the Federal Court provided some helpful commentary and analysis on the application and limitations of patent agent privilege. . PatentProsecution History Now Admissible as Evidence. of the Patent Act was added to make patentprosecution history admissible as evidence in patent proceedings.
On Friday, November 19, the USPTO announced that it will be delaying the $400 fee for patentapplications filed in non-DOCX formats until January 1, 2023.
Furthermore, patentprosecution occurring after the initial filing will vary by each governmental patent office. Some IP offices may present a more challenging patent examination process than others. Do US national stage applications require a subsequent request for examination?
Significantly, the agreement requires India to make substantive changes to its provision obligating a patentapplicant to furnish information about their foreign applications corresponding to their application in India. Sreenath is an independent legal researcher and Adjunct Faculty of Law at Ramaiah Law College.
Patent and Trademark Office (USPTO) announced a Deferred Subject Matter Eligibility Response Pilot Program (the “DSMER Program”). Currently, the USPTO applies a “compact prosecution approach” in examining patentapplications. We provide a brief overview of this program. §101).
PatentApplication No. The GATT Bubble is the term applied to patentapplications filed but not yet granted before the Uruguay Round Agreements Act (URAA), which amended the U.S. patent term to 20 years from the effective filing date, took effect on June 8, 1995. 1.129 (“Rule 129”).
selected address issues such as SPC protection for combination products, double patenting, prosecution history estoppel and the influence of declarations made by the patentee in parallel proceedings, the possibility for national courts to request technical opinions from the EPO under Art. The decisions we (arbitrarily!)
In this post, developed along the lines of a literature review cum blogpost, Yashna Walia has looked through the various government policy documents on AI to see what they have to say about IP! However, he also stated that the government was not considering bringing a law or regulating the growth of artificial intelligence in the country.
Patent and Trademark Office (USPTO) released a Notice of Proposed Rulemaking (NPRM) on May 10, 2024 (89 Fed. 40439), that would dramatically alter patentapplicant and patentee statutory rights in their patent filings by proposing a draconian change to the requirements for submission of a terminal disclaimer (TD).
This period of exclusivity lasts for 20 years from the date the patentapplication was filed. The patent examiners are government employees who are responsible for ensuring that all patentapplications meet the requirements for patent rights to be granted.
Patent and Trademark (USPTO) published a pair of documents in the Federal Register regarding due dates on new document formatting requirements for patentapplications filed with the Office.
The notice was specifically targeted to parties proceeding before both the USPTO and Food and Drug Administration (FDA) and was issued in response to urging by Senators to establish interagency communications aimed in part at eliminating so-called drug patent thickets.
We organize all of the trending information in your field so you don't have to. Join 9,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content